Ambroxol

Therapeutic indications

Ambroxol is indicated for:

Mucolytic therapy

Population group: both men and women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 30 mg/kg body weight per day, divided into four single doses

Treatment 2: Oral - 30 mg 3 times daily

Mucolytic therapy

Population group: both men and women, only children (1 year - 12 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 7.5-15 mg 3 3 times daily

Treatment 2: Intravenous - 30 mg/kg body weight per day, divided into four single doses

Contraindications

Ambroxol is contraindicated in the following cases:

Pregnancy

Pregnancy

Breast-feeding

Lactation

Antitussives or with drugs that have an atropic effect

at least one of
Other cough suppressants
Atropine

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2016: FLAVAMED HUSTENSAFT Oral solution
< Previous: Overview
Next: Precautions >